ELI-005
A candidate COVID-19 subunit vaccine.
General information
ELI-005 is a candidate protein subunit vaccine composed of SARS-CoV-2 Spike protein (S2) receptor binding domain (RBD) adjuvanted with an amphiphile (AMP-CpG). It was shown to induce potent Th1-biased immune response in mice, with high neutralizing antibody titres. The elicited cellular and humoral responses were present in aged mice, as well (Steinbuck et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
Spike protein Protein factor Animal model Mixed substance |
C57BL/6 mice; BALB/c mice | 13.12 | The vaccine was shown to induce potent Th1-biased immune response in mice, with high neutralizing antibody titres and strong CD4+ and CD8+ T-cell responses in blood, spleen, lung tissue, or bronchoalveolar lavage fluid. The formulation enables dose-sparing of Spike RBD with preserved humoral and cellular immune responses. The elicited cellular and humoral responses were present in aged mice, as well. |
Feb/05/2021 |
AI-suggested references
| Link | Publication date |
|---|---|
|
A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
|
Mar/03/2021 |
